NeuBase Therapeutics Inc. (NASDAQ: NBSE) stock fell -7.69% on Monday to $1.20 against a previous-day closing price of $1.30. With 0.63 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.38 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.2612 whereas the lowest price it dropped to was $1.1500. The 52-week range on NBSE shows that it touched its highest point at $11.05 and its lowest point at $0.61 during that stretch. Beta for the stock currently stands at 0.80.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NBSE was down-trending over the past week, with a drop of -8.40%, but this was up by 79.10% over a month. Three-month performance dropped to -55.56% while six-month performance fell -68.75%. The stock lost -89.05% in the past year, while it has lost -68.45% so far this year. A look at the trailing 12-month EPS for NBSE yields -11.85 with Next year EPS estimates of -11.40. For the next quarter, that number is -1.82. This implies an EPS growth rate of 87.30% for this year and 70.00% for next year. EPS is expected to grow by 4.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 51.00%.
Float and Shares Shorts:
At present, 1.69 million NBSE shares are outstanding with a float of 1.37 million shares on hand for trading. On Aug 30, 2023, short shares totaled 0.17 million, which was 5.54% higher than short shares on Jul 30, 2023. In addition to Dr. Dietrich A. Stephan Ph.D. as the firm’s Founder, CEO, Pres & Director, Mr. Todd P. Branning serves as its CFO & Sec..
Institutional Ownership:
Through their ownership of 24.28% of NBSE’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 25.83% of NBSE, in contrast to 20.39% held by mutual funds. Shares owned by individuals account for 2.00%. As the largest shareholder in NBSE with 7.03% of the stake, Armistice Capital LLC holds 166,174 shares worth 166,174. A second-largest stockholder of NBSE, Greenlight Capital, Inc., holds 136,350 shares, controlling over 5.77% of the firm’s shares. Point72 Asset Management LP is the third largest shareholder in NBSE, holding 62,500 shares or 2.65% stake. With a 0.80% stake in NBSE, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 18,981 shares are owned by the mutual fund manager. The Jacob Discovery Fund, which owns about 0.66% of NBSE stock, is the second-largest Mutual Fund holder. It holds 15,655 shares valued at 15185.0. Fidelity Extended Market Index Fu holds 0.30% of the stake in NBSE, owning 7,080 shares worth 6868.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, NBSE reported revenue of $0.00 and operating income of -$8.36M. The EBITDA in the recently reported quarter was -$8.16M and diluted EPS was -$5.20.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NBSE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With NBSE analysts setting a high price target of $200.00 and a low target of $200.00, the average target price over the next 12 months is $200.00. Based on these targets, NBSE could surge 16566.67% to reach the target high and rise by 16566.67% to reach the target low. Reaching the average price target will result in a growth of 16566.67% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded NBSE stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 1,612,200 while 0 shares were sold.
